SIREN : 820854974
BOOST PHARMA is a French company founded 9 years ago, specialized in the sector Activités des agences de publicité. Based in AUBERGENVILLE (78410), this company of category PME shows in 2022 a revenue of 347 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|
| Revenue | 347 204 € | 242 532 € | 174 780 € | 194 591 € | 126 450 € |
| Net income | 72 677 € | 17 700 € | 10 347 € | 18 494 € | -2 683 € |
| EBITDA | 91 491 € | 25 649 € | 16 023 € | 26 563 € | 1 859 € |
| Net margin | 20.9% | 7.3% | 5.9% | 9.5% | -2.1% |
In 2022, BOOST PHARMA achieves revenue of 347 k€. Over the period 2017-2022, the company shows strong growth with a CAGR (compound annual growth rate) of +22.4%. Vs 2021, growth of +43% (243 k€ -> 347 k€). After deducting consumption (0 €), gross margin stands at 347 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 91 k€, representing 26.4% of revenue. Positive scissor effect: EBITDA margin improves by +15.8 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 73 k€, i.e. 20.9% of revenue. This profit can be retained or distributed to shareholders.
347 204 €
347 204 €
91 491 €
88 541 €
72 677 €
26.4%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 0%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 21.8% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.0%
0.0%
21.786%
0.0
81.0%
In 2022, the debt ratio of BOOST PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2022, the financial autonomy of BOOST PHARMA (0.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2022, the repayment capacity of BOOST PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 220.95. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
220.949
0.0
In 2022, the liquidity ratio of BOOST PHARMA (220.95) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2022, the interest coverage of BOOST PHARMA (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 30 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 24 days. The company must finance 6 days of gap between collections and payments. WCR is negative (-49 days): operations structurally generate cash. Notable WCR improvement over the period (-87%), freeing up cash.
-46 862 €
30 j
24 j
0 j
-49 j
Based on 68 transactions of similar company sales
(all years),
the value of BOOST PHARMA is estimated at
197 148 €
(range 67 948€ - 716 476€).
With an EBITDA of 91 491€, the sector multiple of 2.9x is applied.
The price/revenue ratio is 0.22x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 68 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare BOOST PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des agences de publicité
The revenue of BOOST PHARMA in 2022 is 347 k€.
Yes, BOOST PHARMA generated a net profit of 73 k€ in 2022.
The headquarters of BOOST PHARMA is located in AUBERGENVILLE (78410), in the department Yvelines.
The tax return of BOOST PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
BOOST PHARMA operates in the sector Activités des agences de publicité (NAF code 73.11Z). See the 'Sector positioning' section above to compare the company with its competitors.